BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32397016)

  • 1. [Philadelphia chromosome-negative myeloid neoplasms in patients with Philadelphia chromosome-positive chronic myeloid leukemia during tyrosine kinase inhibtor-therapy].
    Yuan T; Wang XY; Lai YY; Qin YZ; Shi HX; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):547-553. PubMed ID: 32397016
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical implications of clonal chromosomal abnormalities in Philadelphia negative cells in CML patients after treated with tyrosine kinase inhibitors.
    Ni H; Sun X; Xu Y; Lyle D; Petersen P; Zhao X; Drum H; You B; Liu D; Liu C; Jiang JG
    Cancer Genet; 2019 Oct; 238():44-49. PubMed ID: 31425925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognosis of clonal chromosomal abnormalities in Philadelphia negative metaphases cells in chronic myeloid leukemia with tyrosine kinase inhibitor therapy].
    Zhao HF; Zhang Y; Hu JY; Li Z; Zhou J; Yu FK; Zu YL; Zhou H; Wei XD; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):209-214. PubMed ID: 30929388
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical Features of Clonal Cytogenetic Abnormalities in Philadelphia-negative Cells Developed During Tyrosine Kinase Inhibitor Treatment.
    Oiwa K; Lee S; Fujita K; Ueda T; Yamauchi T
    Intern Med; 2024 Mar; 63(5):729-732. PubMed ID: 37468240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal chromosomal aberrations in Philadelphia negative cells such as monosomy 7 and trisomy 8 may persist for years with no impact on the long term outcome in patients with chronic myeloid leukemia.
    Wasilewska EM; Panasiuk B; Gniot M; Sawicka A; Kozłowska K; Lewandowski K; Kłoczko J; Midro AT
    Cancer Genet; 2017 Oct; 216-217():1-9. PubMed ID: 29025581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Report of acute myeloid leukemia with "WT1, ATRX, CEBPA, CSMD1, IKZF1, and LRP1B mutation and translocation between chromosome 1 and 19" developing from Philadelphia-negative chronic myeloid leukemia after TKI therapy.
    Zhu H; Yang B; Liu J; Wu W; Ling Y
    Medicine (Baltimore); 2020 Jan; 99(3):e18888. PubMed ID: 32011516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing a second myeloid malignancy in patients with Philadelphia-negative -7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
    Groves MJ; Sales M; Baker L; Griffiths M; Pratt N; Tauro S
    Cancer Genet; 2011 Jan; 204(1):39-44. PubMed ID: 21356190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The influence of additive clonal chromosome abnormalities in Ph negative cells on the efficacy of chronic myeloid leukemia].
    Zhao HF; Zhang Y; Zu YL; Li Z; Zhou J; Yu FK; Hu JY; Wei XD; Song YP
    Zhonghua Nei Ke Za Zhi; 2019 Nov; 58(11):803-807. PubMed ID: 31665854
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
    Deininger MW; Cortes J; Paquette R; Park B; Hochhaus A; Baccarani M; Stone R; Fischer T; Kantarjian H; Niederwieser D; Gambacorti-Passerini C; So C; Gathmann I; Goldman JM; Smith D; Druker BJ; Guilhot F
    Cancer; 2007 Oct; 110(7):1509-19. PubMed ID: 17702093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia.
    Crisan AM; Coriu D; Arion C; Colita A; Jardan C
    J Med Life; 2015; 8(4):502-8. PubMed ID: 26664479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy.
    Nakamura F; Arai H; Nannya Y; Ichikawa M; Furuichi S; Nagasawa F; Takahashi W; Handa T; Nakamura Y; Tanaka H; Nakamura Y; Sasaki K; Miyano S; Ogawa S; Mitani K
    Int J Hematol; 2021 Jun; 113(6):936-940. PubMed ID: 33400143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential role for second‑generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis.
    Ishikawa M; Iriyama N; Tokuhira M; Takaku T; Sato E; Sugimoto KJ; Nakazato T; Fujita H; Kimura Y; Fujioka I; Komatsu N; Asou N; Kizaki M; Hatta Y; Kawaguchi T
    Oncol Rep; 2019 Dec; 42(6):2836-2843. PubMed ID: 31578586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy.
    Wang H; Jin J; Wang Y; Huang X; Huang J
    Ann Hematol; 2013 Dec; 92(12):1625-32. PubMed ID: 23793947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
    Larsson N; Billström R; Lilljebjörn H; Lassen C; Richter J; Ekblom M; Fioretos T
    Cancer Genet Cytogenet; 2010 Jun; 199(2):89-95. PubMed ID: 20471511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia.
    Kumar A; Tilak V; Arora D; Marisha ; Rahul ; Gautam D; Ali A
    Cancer Genet; 2023 Aug; 276-277():12-16. PubMed ID: 37267684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.
    Issa GC; Kantarjian HM; Gonzalez GN; Borthakur G; Tang G; Wierda W; Sasaki K; Short NJ; Ravandi F; Kadia T; Patel K; Luthra R; Ferrajoli A; Garcia-Manero G; Rios MB; Dellasala S; Jabbour E; Cortes JE
    Blood; 2017 Nov; 130(19):2084-2091. PubMed ID: 28835440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of T-cell clonality in a patient with Ph-negative acute lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia.
    Wang L; Zhu K; Zha X; Chen S; Yang L; Chen S; Li Y
    J Hematol Oncol; 2010 Apr; 3():14. PubMed ID: 20377918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course.
    Kurzrock R; Kantarjian HM; Shtalrid M; Gutterman JU; Talpaz M
    Blood; 1990 Jan; 75(2):445-52. PubMed ID: 2403827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.